China Resources Boya Bio-pharmaceutical Group Company Limited (CR Boya Bio-pharmaceutical), a 30.48%-owned subsidiary of China Resources Pharmaceutical Group Limited (CHINARES PHARMA), released audited results for the year ended 31 December 2025.

Revenue climbed 18.69% year on year to RMB2.06 billion, yet profit performance weakened sharply. Net profit attributable to shareholders fell 71.61% to RMB112.70 million, and, after excluding extraordinary items, the company reported a loss of RMB7.76 million versus a RMB301.57 million profit in 2024.

Operating cash generation deteriorated: net cash flow from operating activities declined 79.60% to RMB61.16 million. Basic and diluted earnings per share fell to RMB0.22 from RMB0.79, while weighted average return on equity shrank to 1.51% from 5.36%.

On the balance-sheet side, total assets inched up 2.68% to RMB8.63 billion, whereas net assets attributable to shareholders slipped 0.66% to RMB7.44 billion.

The board proposes a cash dividend of RMB0.73 (tax inclusive) for every 10 shares, subject to approval at the 2025 annual general meeting.

Following the results, CHINARES PHARMA continues to control 41.79% of the voting rights in CR Boya Bio-pharmaceutical, which remains its consolidated subsidiary. Shareholders are advised to refer to the full annual report disclosed on the Shenzhen Stock Exchange website for comprehensive information.